Market cap
$10 Mln
Revenue (TTM)
$22 Mln
P/E Ratio
--
P/B Ratio
1.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -2.45 | 1.33 | 32.21 | 119.12 | -- |
| EBIT | -- | -- | 72.24 | 23.55 | 8.58 |
| Net Profit | -1,024.61 | -211.68 | 62.90 | 20.88 | 0.67 |
| EPS | -724.65 | 19.54 | 93.78 | 25.95 | 14.83 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -707.21 | -2,157.37 | -33.51 | -103.46 | -380.69 |
| Net Margin
| -- | -6,243.73 | -73.52 | -- | -- |
| Return on equity
| -497.70 | -332.82 | -- | 132.32 | -1,364.04 |
| Return on Capital
| -71.18 | -73.44 | -- | 165.50 | -214.19 |
| Return on Assets
| -116.41 | -97.95 | -45.92 | -118.10 | -94.87 |
| Debt to Equity (x)
| -- | -- | 0.00 | -0.13 | -0.40 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
165.50
|
-214.19
|
-164.86
|
-97.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
132.32
|
-1,364.04
|
-261.39
|
-115.04
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-45.92
Lower than Peers by 14.67
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
-45.92
|
-118.10
|
-94.87
|
-136.28
|
-89.21
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
-33.51
Higher than Peers by 49.09
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
-33.51
|
-103.46
|
-380.69
|
-1,637.48
|
-6,507.88
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
-73.52
Higher than Peers by 17.78
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
-73.52
|
-73.83
|
-233.48
|
-1,867.47
|
-5,168.81
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
32.21
Lower than Peers by 21.83
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
32.21
|
0.80
|
1.65
|
4.48
|
--
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
72.24
Higher than Peers by 73.26
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
72.24
|
51.08
|
38.30
|
-37.77
|
-159.58
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
62.90
Higher than Peers by 70.44
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
62.90
|
43.08
|
66.82
|
-40.04
|
-196.51
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
93.78
Higher than Peers by 79.55
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
93.78
|
0.84
|
0.98
|
-0.04
|
-1.12
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
53.34
Higher than Peers by 63.47
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
53.34
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
-0.13
|
-0.40
|
1.92
|
0.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
-0.01
|
-0.13
|
-0.37
|
1.85
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.55
Lower than Peers by 5.26
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
0.55
|
0.46
|
0.85
|
0.82
|
7.72
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
0.33
Lower than Peers by 5.37
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
0.33
|
0.33
|
0.75
|
0.78
|
7.72
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-18.08
Lower than Peers by 16.00
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
-18.08
|
-14.28
|
-13.23
|
-17.16
|
-15.68
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
21.10
Higher than Peers by 2.08
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
21.10
|
17.31
|
31.03
|
37.38
|
115.49
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
0.62
Higher than Peers by 0.56
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
0.62
|
1.60
|
0.41
|
0.07
|
0.01
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
63.09
|
82.39
|
106.79
|
421.82
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
82.79
|
61.39
|
16.46
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
352.07
|
439.22
|
214.25
|
3,682.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
-206.19
|
-295.45
|
-91.00
|
-3,260.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
-0.40
|
-0.01
|
0.00
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.79
Lower than Peers by 3.54
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
1.79
|
-0.35
|
-0.03
|
0.00
|
0.00
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.11
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
-0.11
|
-0.27
|
0.07
|
0.02
|
0.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
10
Lower than Peers by 131
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Agile Therapeutics (AGRX)
|
10
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|